AEYE Health to attend AAO Annual Meeting with diabetic retinopathy screening techonology
AEYE Health will attend the American Academy of Ophthalmology (AAO) Annual Meeting, from October 18-21 in Chicago.
(Image credit: AdobeStock/abricotine)
AEYE Health is set to share the company’s FDA-cleared portable AI solution for autonomous diabetic retinopathy screening at several upcoming medical conferences in October. The device and the screening do not require physician interpretation, enabling on-the-spot and highly accurate retinal screenings at any point of care, either in clinics or at home. The accessibility of screening with this tool can improve early detection of diabetic retinopathy.
AEYE Health will attend the American Academy of Ophthalmology (AAO) Annual Meeting, from October 18-21 in Chicago. The onsite team will be demonstrating how AEYE-DS, the FDA-cleared AI technology, is transforming retinal screening and enhancing patient outcomes.
In addition to the AAO 2024 conference, AEYE Health will also attend:
- CPCA Conference, October 17-18 in Sacramento, CA
- American Academy of Home Care Medicine (AAHCM) Annual Meeting October 18-19 in Phoenix, AZ at booth #310
- HLTH 2024 at booth #2254, from October 21-23 in Las Vegas, NV
Zack Dvey-Aharon, PhD, CEO of AEYE Health, shared his excitement to connect with physicians at these events. In the company’s press release, he is quoted as saying, "We are excited to engage with industry professionals at these events. By offering the only FDA-cleared AI portable screening solution for diabetic retinopathy that does not require physician interpretation, we're helping healthcare providers detect and treat this condition early, bringing screening to patients, whether in clinics or home care settings. AEYE-DS is simply the only practical and affordable solution for screening."
